Idexx Laboratories Inc

  • Health Care
  • Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • www.idexx.com
  • Earnings Score
  • Moat Score
  • Safety Score
  • Final Score
  • Market Cap $38.22B
  • PE 43
  • Debt $620.73M
  • Cash $163.97M
  • EV $38.67B
  • FCF $847.70M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$894.97M
EBIT$1.15B
ROE62%
ROA36%
FCF$847.70M
Equity$1.45B
Growth Stability100%
PE42.7
PEG3.78
PB26.39
P/FCF45.08
P/S9.72
Price/Cash0
Debt/Equity0.43
Debt/FCF0.73
Net Margins24%
Gross Margins61%
Op. Margins29%
Earnings CAGR20%
Sales Growth YoY4%
Sales Growth QoQ5%
Sales CAGR11%
FCF CAGR16%
Equity CAGR45%
Earnings Stability0.94
Earnings Growth YoY3%
Earnings Growth QoQ12%
Earnings CAGR 5Y11%
Sales CAGR 5Y9%
FCF CAGR 5Y12%
Equity CAGR 5Y36%
Earnings CAGR 3Y7%
Sales CAGR 3Y7%
FCF CAGR 3Y35%
Equity CAGR 3Y63%
Market Cap$38.22B
Revenue$3.93B
Assets$3.21B
Total Debt$620.73M
Cash$163.97M
Shares Outstanding80.74M
EV38.67B
Earnings Score95%
Moat Score98%
Safety Score96%
Final Score96%
Working Capital181.4M
Current Ratio1.16
Gross Profit$2.41B
Shares Growth 3y-1%
Equity Growth QoQ-9%
Equity Growth YoY-8%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

SEC Filings

Direct access to Idexx Laboratories Inc (IDXX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2025
    • 10-Q Mar 31
  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Idexx Laboratories Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Idexx Laboratories Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 20%
Stability 94%
loading chart...

Idexx Laboratories Inc Discounted Cash Flow

Fully customizable DCF calculator online for Idexx Laboratories Inc .

= $27B
012345678910TV
fcf$848M$986M$1.1B$1.3B$1.6B$1.8B$2.1B$2.4B$2.9B$3.3B$3.9B$39B
DCF$897M$949M$1B$1.1B$1.1B$1.2B$1.3B$1.3B$1.4B$1.5B$15B
Value$27B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins12%13%13%17%18%21%23%20%23%23%24%
ROA-23%24%32%30%30%38%33%34%34%36%
ROE--205%-489%-4K%241%92%108%112%57%56%62%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF-2.22.032.122.31.771.462.1410.970.73
Debt over Equity-7.11-5.49-11.27-65.183.931.521.341.390.520.490.43
Growth Stability---100%100%100%100%100%100%100%100%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-11%11%12%9%12%19%5%9%6%9%
Earnings YoY growth-16%19%43%13%36%28%-9%24%5%11%
Equity YoY growth-29%-50%-83%-2K%256%9%-12%144%7%36%
FCF YoY growth-102%11%-5%7%78%18%-38%96%5%12%